FLONASE ALLERGY RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLONASE ALLERGY RELIEF (FLONASE ALLERGY RELIEF).
Glucocorticoid agonist; binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal mucosal inflammation.
| Metabolism | Hepatic via CYP3A4 to active metabolite fluticasone propionate; also hydrolyzed by esterases. |
| Excretion | Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% as unchanged drug, with the remainder as metabolites in feces (approximately 90%) and urine (approximately 5%). |
| Half-life | Terminal elimination half-life is approximately 10 hours (range 7–14 hours), reflecting slow release from tissue binding sites; accumulation occurs with once-daily dosing, achieving steady state in 1–2 weeks. |
| Protein binding | Approximately 91% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 4.2 L/kg (range 2.5–6.5 L/kg), indicating extensive tissue distribution and sequestration in lipid-rich compartments. |
| Bioavailability | Intranasal: Absolute bioavailability is <1% due to extensive first-pass hepatic metabolism and low systemic absorption; systemic exposure is minimal at recommended doses. |
| Onset of Action | Intranasal: Symptom relief begins within 12 hours after the first dose, with maximum effect observed after several days of regular use. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing; continuous use is required for sustained relief of allergic rhinitis symptoms. |
| Molecular Weight | 500.57 |
2 sprays (50 mcg each) per nostril once daily, total daily dose 200 mcg. If inadequate, may increase to 2 sprays per nostril twice daily (400 mcg/day).
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment as systemic bioavailability may increase. |
| Pediatric use | Aged 4-11 years: 1 spray (50 mcg) per nostril once daily (100 mcg/day). Aged 12 years and older: same as adult. |
| Geriatric use | No specific dose adjustment; use same as adult dosing with monitoring for adverse effects. |
| 1st trimester | Insufficient human data; animal studies show no teratogenicity at high doses. Use only if benefit outweighs risk. |
| 2nd trimester | No known risk in human studies; fluticasone propionate is a corticosteroid with low systemic bioavailability. Use with caution. |
| 3rd trimester | Avoid use near term due to potential for adrenal suppression in neonate. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for FLONASE ALLERGY RELIEF (FLONASE ALLERGY RELIEF).
| Placental transfer | Limited data; molecular weight (~500 Da) suggests likely placental passage. Systemic bioavailability after intranasal use is <2%, resulting in minimal fetal exposure. |
| Breastfeeding | Fluticasone propionate is excreted in human milk in low amounts. Intranasal administration produces low systemic levels; unlikely to cause adverse effects in nursing infant. Use with caution. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to fluticasone propionate or any excipientsUntreated localized nasal fungal, bacterial, or viral infections
| Precautions | Nasal septum perforation, Localized Candida infections, Growth suppression in children, HPA axis suppression with prolonged high doses, Hypersensitivity reactions (e.g., urticaria, anaphylaxis), Ocular effects (e.g., glaucoma, cataracts) |
| Food/Dietary | No clinically significant food interactions. Avoid alcohol if it exacerbates rhinitis symptoms. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Probably compatible) |
| Teratogenic Risk | Fluticasone propionate (FLONASE ALLERGY RELIEF) is an intranasal corticosteroid. In animal studies, high systemic doses caused teratogenic effects, but intranasal administration yields minimal systemic absorption. No increased risk of major malformations has been observed in human studies with inhaled or intranasal corticosteroids. First trimester: No evidence of significant risk; second and third trimesters: No increased risk of fetal harm; however, chronic high-dose systemic corticosteroids are associated with intrauterine growth restriction and adrenal suppression. Overall, intranasal fluticasone is considered low risk in pregnancy. |
| Fetal Monitoring | No specific fetal monitoring is required for intranasal fluticasone use. However, if used for prolonged periods or at higher than recommended doses, consider monitoring maternal adrenal function. For pregnant women, standard prenatal care is sufficient. |
| Fertility Effects | No known adverse effects on human fertility. In animal studies, high systemic doses caused reduced fertility, but intranasal fluticasone exhibits minimal systemic absorption. At recommended intranasal doses, no impact on fertility is expected. |
| Fluticasone propionate nasal spray (Flonase Allergy Relief) is a corticosteroid that requires regular use for 3-7 days to achieve maximal effect. It is first-line for moderate-to-severe allergic rhinitis. Advise patients to blow nose before use, tilt head slightly forward, and aim spray away from nasal septum to minimize epistaxis. Shake gently before each use. Do not use beyond 6 months without medical evaluation. |
| Patient Advice | Use daily for best results; do not expect immediate relief. · Blow nose gently before each use. · Tilt head forward slightly and insert nozzle into nostril. · Aim spray away from the center of the nose (nasal septum). · Do not use more than 2 sprays per nostril daily (for adults). · Rinse the cap and nozzle with warm water after each use, and dry thoroughly. · Side effects may include nasal irritation, nosebleeds, or headache. · If pregnant or breastfeeding, consult doctor before use. |